1 week Ago By ABMN Staff
Legal & General Group Plc lifted its position in Spyre Therapeutics, Inc. ( NASDAQ:SYRE – Free Report ) by 14.8% in the 4th quarter, Holdings Channel.
com reports. The institutional investor owned 37,490 shares of the company’s stock after acquiring an additional 4,824 shares during the period. Legal & General Group Plc’s holdings in Spyre Therapeutics were worth $873,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Huntington National Bank bought a new position in shares of Spyre Therapeutics in the fourth quarter valued at $34,000. Mirae Asset Global Investments Co.
Ltd. bought a new position in Spyre Therapeutics during the fourth quarter worth $46,000. KLP Kapitalforvaltning AS bought a new position in Spyre Therapeutics during the fourth quarter worth $182,000.
Arizona State Retirement System boosted its position in Spyre Therapeutics by 38.4% during the fourth quarter. Arizona State Retirement System now owns 10,115 shares of the company’s stock worth $235,000 after purchasing an additional 2,805 shares during the period.
Finally, Teacher Retirement System of Texas bought a new position in Spyre Therapeutics during the fourth quarter worth $242,000. 80.39% of the stock is owned by institutional investors.
Spyre Therapeutics Trading Down 5.4 % Shares of NASDAQ:SYRE opened at $14.13 on Monday.
The firm has a 50 day moving average of $16.57 and a 200-day moving average of $23.24.
Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $40.
49. The stock has a market capitalization of $851.70 million, a PE ratio of -1.
89 and a beta of 3.05. Wall Street Analyst Weigh In A number of equities analysts have commented on the stock.
Wedbush reaffirmed an “outperform” rating and set a $65.00 price objective on shares of Spyre Therapeutics in a research report on Monday, January 13th. Leerink Partnrs raised shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, April 8th.
Wolfe Research started coverage on Spyre Therapeutics in a report on Tuesday, March 18th. They set an “outperform” rating and a $27.00 target price for the company.
Leerink Partners started coverage on Spyre Therapeutics in a report on Tuesday, April 8th. They set an “outperform” rating and a $45.00 target price for the company.
Finally, The Goldman Sachs Group raised Spyre Therapeutics to a “strong-buy” rating in a report on Tuesday, February 18th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.
com, Spyre Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $49.57. Check Out Our Latest Research Report on SYRE About Spyre Therapeutics ( Free Report ) Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). Featured Stories Want to see what other hedge funds are holding SYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spyre Therapeutics, Inc.
( NASDAQ:SYRE – Free Report ). Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
